Autotransfusion Systems Market Size is Projected to Reach US$ 466.8 Million by 2033| Fact.MR

The autotransfusion systems is expected to reach US$ 315.4 million in 2023 and grow at a compound annual growth rate (CAGR) of 4% between 2023 and 2033, according to the most recent industry analysis conducted by market research and competitive intelligence company Fact.MR.

During a particular surgical procedure, a piece of medical technology called an autotransfusion system collects and processes the patient's blood, obviating the need for external blood transfusions. This gadget's novel operating architecture makes it possible for it to provide vital autologous blood during a variety of device applications.

The rising number of surgical procedures, such as liver or other organ transplant surgeries, is expected to fuel sales growth throughout the forecast period and increase demand for autotransfusion systems.

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐓𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭:
https://www.factmr.com/connectus/sample?flag=S&rep_id=8327

By 2033, the autotransfusion systems market is projected to grow to a value of US$ 466.8 million worldwide.
Over the estimated timeframe, the Chinese market is expected to grow at a high compound annual growth rate of 4%.
Over the next ten years, the demand for autotransfusion products is predicted to grow at a CAGR of 4.5%.
Over the course of the projected period, autotransfusion accessory sales are expected to grow at a 3% CAGR.

"There is high demand for autotransfusion systems from hospitals due to rising rate of patient intake for getting advanced treatment procedures," says a Fact.MR analyst.

𝐑𝐞𝐜𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭𝐬

In November 2021, Fresenius SE & Co. KGaA and Omnicell, Inc. partnered to offer hospitals and health systems in the United States state-of-the-art innovative pharmacy technology.

ProCell, the first medical device developed by ProCell Surgical Inc. to effectively automate the labor-intensive and obsolete surgical sponge-blood recovery procedure for intraoperative autotransfusion, was unveiled in June 2020.

𝐆𝐞𝐭 𝐂𝐮𝐬𝐭𝐨𝐦𝐢𝐳𝐚𝐭𝐢𝐨𝐧 𝐨𝐧 𝐭𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐟𝐨𝐫 𝐒𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐒𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐬:
https://www.factmr.com/connectus/sample?flag=RC&rep_id=8327

𝐂𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐢𝐯𝐞 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞

To increase revenue, a number of autotransfusion system suppliers are implementing a variety of marketing techniques, including joint ventures, partnerships, local sourcing, raising the bar for their products, and more.

LivaNova holds a leading position in the industry for autotransfusion systems. LivaNova's cardiovascular product line includes cutting-edge autotransfusion devices. The business is recognized as a world leader in autotransfusion because of its experience and commitment to researching innovative solutions. LivaNova's most advanced, user-friendly, and powerful ATS system, XTRA, has been supporting doctors since 2010. It blends cutting-edge technology capabilities with powerful performance and user-friendliness. XTRA has reduced the risks associated with allogeneic transfusion and shortened hospital stays for over a million patients.
Fresenius is a leading brand in the autotransfusion systems market. Fresenius Kabi, a subsidiary of the business, offers a comprehensive range of autotransfusion devices. CATSmart is a new continuous red cell separation method based on continuous flow technology that Fresenius Kabi developed for recycling blood intra- and post-cardiac, orthopedic, or vascular procedures. The only autotransfusion system available on the market, CATSmart, uses a continuous flow approach to guarantee consistent quality red blood cells (RBCs) that are accessible quickly whenever needed.
Haemonetics has carved out a significant niche for itself in the market for autotransfusion systems. The organization provides a large selection of blood, plasma, and whole blood products. Hospitals may recover and redistribute a patient's high-quality blood after medium to high blood loss procedures, including cardiac, orthopedic, trauma, transplant, vascular, and OBGYN surgeries, by utilizing the company's Cell Saver Elite technology.

𝐌𝐚𝐫𝐤𝐞𝐭 𝐅𝐫𝐨𝐧𝐭𝐫𝐮𝐧𝐧𝐞𝐫𝐬

Atrium Medical Corporation (A Part of Getinge Group)
Becton, Dickinson and Company
Beijing ZKSK Technology Co., Ltd.
Braile Biomédica
Fresenius Medical Care AG & Co. KGaA
Gen World Medical Devices
Haemonetics Corporation
Livanova PLC
Medtronic PLC
Redax

𝐑𝐞𝐜𝐞𝐧𝐭 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭𝐬

Cardiovascular diseases rank among the world's top causes of death. It is believed that the accumulation of cholesterol and other chemicals in the coronary arteries is the cause of many coronary artery diseases (CAD).

The National Center for Biotechnology Information (NCBI) estimates that 5.8 million people in the US and over 23 million people globally suffer from heart failure.
Therefore, the growing number of heart-related procedures is fueling the demand for autotransfusion devices. The growing use of autologous blood transfusion in significant orthopedic and cardiovascular procedures is anticipated to drive market expansion in the North America region over the forecast period, along with the existence of a developed healthcare infrastructure.

Due to the constantly increasing rates of trauma and accidents in nations like Germany, France, and the United Kingdom as well as the strong emphasis on implementing intraoperative and postoperative cell salvage methods, Europe is expected to offer substantial growth potential for market competitors.

𝐂𝐨𝐧𝐭𝐚𝐜𝐭:

US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
Email: sales@factmr.com

𝐀𝐛𝐨𝐮𝐭 𝐅𝐚𝐜𝐭.𝐌𝐑

We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.

This release was published on openPR.